Universal CAR-Ts for Treating Cancer

  • Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

Chimeric Antigen Receptor T-Cells (CAR-Ts) are one of the revolutionary technologies of the twenty-first century, invented by Prof. Zelig Eshhar at the Weizmann Institute of Science. FDA approvals for CAR T cells against B-ALL and DLBCL pave the way for CAR-T cell application against other types of cancers.

However, the CAR-T technology still suffers from a number of shortfalls. While the efficacy against B cell cancers has been dramatic, the responses of other tumor types, and particularly solid tumors, has been much more modest. In addition, the logistical complexity and the overall labor involved in using the patient’s own cells are significant. Consequently, there are significant advantages to shift away from autologous cells (a patient’s own cells) and to using allogeneic cells (donor cells) as the basis of CAR-Ts, to create a truly “off-the-shelf” treatment.


The Solution

The group of Prof. Eshhar has developed a method for an adoptive cell therapy, such that cells from donors can be applied in a patient. The technology has already shown positive results in mouse models as well as superiority over autologous CART cells, and Prof. Eshhar’s team is looking to translate the work into human subjects.

Technology Essence

The basis of the Universal CAR-T technology is that it uses a fundamental understanding of the immune system to allow for adoptive cell therapy. The Eshhar’s group protocol uses both controlled lympho-depletion and repurposes the FDA approved drug Fingolimod (Gilenya), which sequesters a patient’s lymphocytes to the lymphoid organs. These two actions permit allogenic T-Cells to effectively function, creating an optimal therapeutic window for the CAR-Ts to destroy the malignancy. In this way the graft versus host reactivity of the allogeneic CAR T cells is redirected against the cancer. This redirection achieves two goals: first, it inhibits the development of graft versus host disease, and second it boosts the effectiveness of the treatment. Present experimental work has shown that allogeneic CAR T cells are superior to autologous CAR T cells in mouse models. The technology also has numerous advantages including enhanced efficacy, a simplified production process for CAR-Ts, non-exhausted cells leading to a better outcome, and a general flexibility as the technology could function regardless of target (e.g. not CD19 exclusive) or even cell type (e.g. could be applied for TCRs, or next generation

CAR therapies).

Applications and Advantages

A method for Universal CAR-Ts

Simplifying the application of CAR-Ts

Reduction of cost

More effective CAR-T cells

Intellectual property status

  • Granted Patent
  • Patent application number :USA Granted: 9,623,049

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Clinical Research, Trials
  • Medical Research
  • Biology / Biotechnology
  • Medical/health
  • Pharmaceuticals/fine chemicals

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools


Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support